‘Toujeo,’ next-generation basal insulin, has been approved, competing against ‘Tresiba’
A number of next-generation long-acting basal insulin, which decreased risks in hypoglycemia occurrence, is about to enter the domestic market.
According to the industry concerned on the 14th, Sanofi-Aventis’s next-generation basal insulin, ‘Toujeo Solostar(insulin glargine)’ has acquired approv...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
